V5 Ultimate
Guide

Pharmaceutical GMP readiness in Australia

Australia's Therapeutic Goods Administration (TGA) regulates medicines under the Therapeutic Goods Act 1989. Australian GMP is the PIC/S Guide to GMP (PE 009, current version) plus annexes, adopted by reference. Domestic manufacturers need a manufacturing licence; overseas manufacturers supplying the Australian Register of Therapeutic Goods (ARTG) need a GMP Clearance (CV — Compliance Verification, MRA, or Desktop). TGA is a long-standing PIC/S member with an EU–AU MRA for human medicines. This guide covers the Australia layer over an ICH Q10 PQS.

Start free trial Free trial, no credit card, onboard in days, not months.

Regulator and legal basis

TGA is the federal regulator. Statutes: Therapeutic Goods Act 1989; Therapeutic Goods Regulations 1990; Therapeutic Goods (Manufacturing Principles) Determination which adopts PIC/S PE 009 as Australian GMP. Sponsors (Australian-resident entities) list products on the ARTG.

Manufacturing licence and GMP Clearance

Australian sites need a TGA manufacturing licence. Overseas manufacturers do not need an Australian licence but every overseas site referenced on an ARTG entry needs a GMP Clearance, granted via one of three pathways: MRA Clearance (using EU/EEA/UK/Swiss/Canadian GMP certificates under MRA), Compliance Verification Clearance (CV — TGA evaluates an inspection report and evidence), or, in narrow cases, Desktop Assessment for low risk.

Release model and distribution

Release for supply in Australia is performed by an authorised person under the sponsor/manufacturer's QMS — no statutory QP. Distribution follows the Australian Code of Good Wholesaling Practice (GWP) and state-level licensing. Serialization is not federally mandated.

Inspection style and common findings

TGA inspections use PIC/S classifications (critical/major/other). Common findings: Annex 1 contamination control, data integrity (ALCOA+), validation lifecycle (Annex 15), and supplier qualification. TGA publishes outcomes selectively and may suspend or cancel the manufacturing licence or ARTG entry.

A 90–180 day Australia readiness path

Days 0–30: identify the sponsor, ARTG entries, and overseas sites needing GMP Clearance. Days 31–90: assemble MRA evidence (EU/UK/CH/CA certificates and inspection reports) or prepare a CV application. Days 91–180: apply for GMP Clearance; respond to TGA queries; ensure the Australian sponsor holds the technical file and release records.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Industries this hits hardest

Frequently asked

Do we need a TGA inspection if we have an EU GMP certificate?
Generally no — the MRA Clearance pathway accepts current EU/EEA/UK/Swiss/Canadian GMP certificates for human medicines. TGA may still inspect for risk-based reasons or for product classes outside the MRA.
What is the difference between MRA Clearance and CV Clearance?
MRA Clearance leverages a current GMP certificate from an MRA partner authority. CV Clearance is used when no MRA applies — TGA evaluates an inspection report (often from a PIC/S partner) plus evidence. CV is slower and more document-intensive.
Does Australia have a QP?
No statutory QP. The licensed manufacturer's authorised person releases batches under PIC/S Part I; for overseas-manufactured product, the EU/UK QP certification is normally relied on via MRA.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Spot something off? .